Evidence map›Paper›PMID 26503935›Full record

ArticleNature communications2015

The γ-tubulin-specific inhibitor gatastatin reveals temporal requirements of microtubule nucleation during the cell cycle.

Takumi Chinen, Peng Liu, Shuya Shioda, Judith Pagel, Berati Cerikan, Tien-Chen Lin, Oliver Gruss, Yoshiki Hayashi, Haruka Takeno, Tomohiro Shima and 6 more

Open access · goldAbstract read
In one paragraph

Article in Nature communications, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
3.0field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 58 citations in OpenAlex.

  1. Article
  2. Article
  3. Targeting TUBG1 in RB1-negative tumors.FASEB journal : official publication of the Federation of American Societies for Experimental Biology · 2025
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. How Microtubules Build the Spindle Branch by Branch.Annual review of cell and developmental biology · 2022
    Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 6 institutions in 2 countries.

Takumi ChinenGraduate School of Life and Environmental Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8572, Japan.
Peng LiuZentrum für Molekulare Biologie der Universität Heidelberg, ZMBH-DKFZ Alliance, Im Neuenheimer Feld 282, Heidelberg 69120, Germany.
Shuya ShiodaGraduate School of Pure and Applied Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8571, Japan.
Judith PagelZentrum für Molekulare Biologie der Universität Heidelberg, ZMBH-DKFZ Alliance, Im Neuenheimer Feld 282, Heidelberg 69120, Germany.
Berati CerikanZentrum für Molekulare Biologie der Universität Heidelberg, ZMBH-DKFZ Alliance, Im Neuenheimer Feld 282, Heidelberg 69120, Germany.
Tien-Chen LinZentrum für Molekulare Biologie der Universität Heidelberg, ZMBH-DKFZ Alliance, Im Neuenheimer Feld 282, Heidelberg 69120, Germany.
Oliver GrussZentrum für Molekulare Biologie der Universität Heidelberg, ZMBH-DKFZ Alliance, Im Neuenheimer Feld 282, Heidelberg 69120, Germany.
Yoshiki HayashiDepartment of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan.
Haruka TakenoDepartment of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan.
Tomohiro ShimaLaboratory for Cell Polarity Regulation, RIKEN Quantitative Biology Center, Suita 565-0874, Japan.
Yasushi OkadaLaboratory for Cell Polarity Regulation, RIKEN Quantitative Biology Center, Suita 565-0874, Japan.
Ichiro HayakawaDivision of Applied Chemistry, Graduate School of Natural Science and Technology, Okayama University, 3-1-1 Tsushima-naka, Kita-ku, Okayama 700-8530, Japan.
Yoshio HayashiDepartment of Medicinal Chemistry, Tokyo University of Pharmacy and Life Sciences, Hachioji, Tokyo 192-0392, Japan.
Hideo KigoshiGraduate School of Pure and Applied Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8571, Japan.
Takeo UsuiGraduate School of Life and Environmental Sciences, University of Tsukuba, 1-1-1 Tennodai, Tsukuba 305-8572, Japan.ORCID http://orcid.org/0000-0003-2377-7499
Elmar SchiebelZentrum für Molekulare Biologie der Universität Heidelberg, ZMBH-DKFZ Alliance, Im Neuenheimer Feld 282, Heidelberg 69120, Germany.
Heidelberg University · DEUniversity of Tsukuba · JPTokyo University of Pharmacy and Life Sciences · JPOkayama University · JPRIKEN BioResource Research Center · JPTokyo University of Science · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibitors of microtubule (MT) assembly or dynamics that target α/β-tubulin are widely exploited in cancer therapy and biological research. However, specific inhibitors of the MT nucleator γ-tubulin that would allow testing temporal functions of γ-tubulin during the cell cycle are yet to be identified. By evolving β-tubulin-binding drugs we now find that the glaziovianin A derivative gatastatin is a γ-tubulin-specific inhibitor. Gatastatin decreased interphase MT dynamics of human cells without affecting MT number. Gatastatin inhibited assembly of the mitotic spindle in prometaphase. Addition of gatastatin to preformed metaphase spindles altered MT dynamics, reduced the number of growing MTs and shortened spindle length. Furthermore, gatastatin prolonged anaphase duration by affecting anaphase spindle structure, indicating the continuous requirement of MT nucleation during mitosis. Thus, gatastatin facilitates the dissection of the role of γ-tubulin during the cell cycle and reveals the sustained role of γ-tubulin.

Indexed as

Cell CycleCell LineHumansIsoflavonesMicrotubulesSpindle ApparatusTubulinTubulin Modulatorsglaziovianin AIsoflavonesTubulinTubulin Modulators

Identifiers

PMID26503935
PMCPMC4640066
OpenAlexW2253559531

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.